Skip to main content
Premium Trial:

Request an Annual Quote

NanoString, Leica Enter Comarketing Agreement

NEW YORK (GenomeWeb) – NanoString said today it has entered a comarketing agreement with Leica Biosystems.

Under the agreement, the companies will create a research workflow integrating NanoString's GeoMx Digital Spatial Profiling (DSP) instrument with Leica's Bond RX autostainer. Leica will be able to promote the GeoMx technology to its Bond RX customers, and NanoString will promote the Bond RX system to its GeoMX DSP customers.

According to NanoString, the integration will allow for more streamlined processing of tissue samples for applications like biomarker discovery.

Launched this week at the American Association for Cancer Research annual meeting, the GeoMx DSP platform allows for multiplexed spatial profiling of RNA and proteins.

"We have already used the Bond RX autostainer for many successful projects performed under our DSP Technology Access Program," Brad Grey, president and CEO of NanoString, said in a statement. "With the Bond RX and GeoMx DSP's compatible throughput, the two platforms together will provide an integrated and complete solution and should become a workhorse for any spatial profiling researcher."

Financial and other terms of the agreement were not disclosed.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.